Job Description - VP, Translational Research (230520) Overview The VP, Translational Research is a leadership position within the Research organization. Primary responsibilities include identifying indications for a portfolio of preclinical targets along with creating initial clinical development plans to expedite filing of CTAs/INDs with the strongest basis for proof of concept in Phase 1. The current Alnylam portfolio is therapeutic area agnostic and spans cardiometabolic, neurological, orphan, renal, and ocular diseases with plans to expand into numerous other indications and tissues. The successful candidate will play a central role in the identification of new targets from multiple sources including Alnylam's extensive access to large genotype-phenotype datasets (e.g., UK biobank and Our Future Health), scientific literature, and by working with Research teams engaged in novel biological research related to putative targets. The role will also be critical in the identification of preclinical and clinical biomarkers and help create momentum for programs being driven to the clinic. This is a new role within Research with the potential to form a group after showing success. In addition, the VP, Translational Research will foster key strategic partnerships and be responsible for the Research/nonclinical and Clinical Development interfaces, ensuring awareness/alignment of the preclinical portfolio, indication strategy, and development plans. Externally, this position is expected to be active in garnering support for the pipeline, including at Alnylam's annual R&D Day, and helping build strong relationships with world-class key opinion leaders including setting up KOL panels and other key interactions. Summary of Key Responsibilities Identify targets/indications where Alnylam technology can deliver transformative medicines. Lead cross-functional teams to identify and prioritize indications for targets within Research. Drive external interactions with key opinion leaders to develop indication and early clinical strategy and identify targets and diseases of interest. Help make prioritization decisions around the internal early-stage portfolio. Create Phase 1 clinical development plans that enable robust assessment of pharmacodynamics and provide early indications of efficacy (where possible). Ensure program readiness for Phase 1 by driving biomarker strategy. Actively participate in target discovery efforts including working closely with the statistical genetics team to enable discovery of new targets from genotype-phenotype datasets. Lead the interface with Clinical Development to ensure smooth transition of discovery programs into the clinic and alignment with research plans. Work closely with commercial and portfolio management functions to optimize the indications for preclinical assets in line with Alnylam's broader strategy. Qualifications MD or MD/PhD with Board certification in internal medicine or specialty preferred. 10 years of industry experience. Proven track record of leading targets from research to clinical arenas. Experience in bench/lab work and a strong track record of publications. Inquisitive, discovery mindset with experience in early clinical development and discovery research. Expertise in development of Phase 1 development plans and CTA/IND filing. Passion for biomarker discovery and development in the context of fast-moving research programs. Comfort and experience with target discovery from animal models to human genetic datasets. Interpersonal skills with a highly collaborative approach to achieving goals critical. Demonstrated ability to work effectively across the organizational matrix. Excellent communication and presentation skills are necessary to represent team efforts at key internal governance meetings and externally in various scientific and other forums. J-18808-Ljbffr